Advertisement

Ondansetron: A Novel Anti-anxiety Agent

  • F. S. Abuzzahab
Chapter

Abstract

Although the widely used benzodiazepines for control of anxiety have met with high patient acceptance, there is a hesitation about long-term use owing to the possibility of dependence. The new azaspirodecanedione compounds such as buspirone (Buspar) are free from dependence but raise the spectre of tardive dyskinesia since they are derivatives of the butyro-phenones. Furthermore, the azaspirodecanediones have a limitation in that the onset of the anti-anxiety benefit might take a week or two. Therefore, ondansetron, a novel compound with antianxiety properties, was studied in outpatients who met the American Psychiatric Association Diagnostic and Statistical Manual III (DSM-III) criteria for generalized anxiety disorder with or without panic attacks. This report is on the methodological difficulties encountered in such a clinical investigation.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Butler, A., Hills, J. M., Ireland, S. J., Jordan, C. C., and Tyers, M. B. (1988). Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors. Brit. J. Pharmacol., 94, 397–412.CrossRefGoogle Scholar
  2. Cohen, M. L., Bloomguist, W., Gidda, J., and Lacefield, W. (1989). Comparison of the 5-HT3 receptor antagonist properties of ICS 205–930, GR 38032F and zacopride. J. Pharmacol. Exp. Ther., 248, 197–201.PubMedGoogle Scholar
  3. Gaddum, J. H., and Picarelli, Z. P. (1957). Two kinds of tryptamine receptor. Br. J. Pharmacol Chemother., 12, 323–8.PubMedCentralPubMedCrossRefGoogle Scholar
  4. Jones, B. J., Costall, B., Domeney, A. M., Kelly, M. E., Naylor, R. J., Oakley, N. R., and Tyers, M. B. (1988). The potential anxiolytic activity of GR 38032F, a 5-HT3-receptor antagonist. Brit. J. Pharmacol., 93, 985–93.CrossRefGoogle Scholar
  5. Kris, M. G., Gralla, R. J., Clark, R. A. and Tyson, L. B. (1988). Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy. J. Clin. Oncol., 6, 659–62.PubMedGoogle Scholar
  6. Marty, M., Droz, J. P., Pouillart, P., Paule, B., Brion, N. and Bors, J. (1989). GR38032F, a 5-HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting. Canc. Chemother. Pharmacol., 23, 389–91.CrossRefGoogle Scholar
  7. Peroutka, S. J., and Snyder, S. H. (1979). Multiple serotonin receptors: differential binding of [3H]-5-hydroxytryptamine [3H]-lysergic acid diethylamide and [3H]-spiroperidol. Mol. Pharmacol., 16, 687–99.PubMedGoogle Scholar

Copyright information

© Macmillan Publishers Limited 1991

Authors and Affiliations

  • F. S. Abuzzahab
    • 1
  1. 1.University of Minnesota HospitalsMinneapolisUSA

Personalised recommendations